Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Baylor College of Medicine
Baylor College of Medicine
Baylor College of Medicine
National Cancer Institute (NCI)
Xijing Hospital of Digestive Diseases
Jagiellonian University
Chinese University of Hong Kong
Samsung Medical Center
AdventHealth
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Shanghai Zhongshan Hospital
Azienda USL Reggio Emilia - IRCCS
Assiut University
University Hospital, Limoges
City of Hope Medical Center
Pirogov Russian National Research Medical University
City of Hope Medical Center
Turkish Society of Colon and Rectal Surgery
Portsmouth Hospitals NHS Trust
Centre Hospitalier Universitaire Saint Pierre
Fujian Cancer Hospital
Memorial Sloan Kettering Cancer Center
Chinese University of Hong Kong
Western Sydney Local Health District
Western Sydney Local Health District
Western Sydney Local Health District
Western Sydney Local Health District
Western Sydney Local Health District
Western Sydney Local Health District
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hospital Universitario 12 de Octubre
Azienda USL Reggio Emilia - IRCCS
National Cancer Center, Korea
Chinese University of Hong Kong
Carol Davila University of Medicine and Pharmacy
Asian Institute of Gastroenterology, India
Baylor College of Medicine
Istituto Clinico Humanitas
Universitätsklinikum Hamburg-Eppendorf
Société Française d'Endoscopie Digestive
Tenwek Hospital
Chinese University of Hong Kong
Erasme University Hospital
Changhai Hospital
Military University Hospital, Prague
Universitätsklinikum Hamburg-Eppendorf
Western Sydney Local Health District
Universitätsklinikum Hamburg-Eppendorf
University of Ulm